Compare SGRY & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SGRY | IOVA |
|---|---|---|
| Founded | 2004 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 2015 | 2008 |
| Metric | SGRY | IOVA |
|---|---|---|
| Price | $13.23 | $14.23 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 10 |
| Target Price | ★ $18.82 | $10.70 |
| AVG Volume (30 Days) | 2.1M | ★ 12.3M |
| Earning Date | 11-09-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 54.14 | 14.84 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,145,438,000.00 | N/A |
| Revenue This Year | N/A | $54.93 |
| Revenue Next Year | N/A | $40.91 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.41 | $1.76 |
| 52 Week High | $23.44 | $15.06 |
| Indicator | SGRY | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 46.73 | 86.63 |
| Support Level | $13.26 | $3.57 |
| Resistance Level | $15.02 | N/A |
| Average True Range (ATR) | 0.78 | 0.65 |
| MACD | 0.03 | 0.45 |
| Stochastic Oscillator | 32.02 | 95.63 |
Surgery Partners Inc is a healthcare services company with an integrated outpatient delivery model focused on providing quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. It has one reportable segment: Surgical Facilities, which includes the operation of ASCs, surgical hospitals, anesthesia services, and multi-specialty physician practices, which earn revenues from contracts with patients in which the performance obligations are to provide health care services.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.